Voi Mounjaro — what this search tells us and what you actually need to know

Step 1, Understanding what Mounjaro actually is

Mounjaro is the brand name for tirzepatide, made by Eli Lilly. It is a once-weekly subcutaneous injection delivered via a pre-filled KwikPen, where each pen contains four weekly doses. What makes it distinct from other weight-loss injections is the mechanism: it activates both the GIP and GLP-1 receptors involved in appetite regulation and blood-sugar control. Most comparable medicines target only GLP-1. Activating both pathways slows gastric emptying, increases the feeling of fullness, and reduces overall appetite. The tirzepatide overview on this site covers the pharmacology in more depth if you want it.

It is important to hold that mechanism against realistic expectations. Mounjaro is not a standalone fix; it is licensed alongside a reduced-calorie diet and increased physical activity. In the SURMOUNT-1 clinical trial, published in the New England Journal of Medicine, adults on the 15 mg dose lost an average of around 20–21% of body weight over 72 weeks, significant results, always alongside lifestyle changes.

You can find broader context on weight management approaches on the weight loss treatments overview, including how injectable and oral options compare.

Step 2, Checking whether you meet the licensed criteria

Mounjaro's UK licence covers adults with a BMI of 30 or above, or a BMI of 27 or above alongside at least one weight-related condition such as high blood pressure, type 2 diabetes, high cholesterol, or obstructive sleep apnoea. A BMI above the threshold is not a guarantee of approval, the prescriber reviews the full clinical picture, including your medical history and any medicines you already take.

NICE's appraisal of tirzepatide, TA1026, sets a higher bar for NHS prescribing: a BMI of 35 or above plus at least one weight-related comorbidity, with thresholds reduced by 2.5 kg/m² for some ethnic backgrounds. Private prescribing follows the licensed SmPC criteria, which are somewhat broader. A quick check: use the NHS BMI calculator to confirm your starting number before a consultation, it takes under a minute and gives you one concrete data point to bring to the prescriber.

People who are pregnant, breastfeeding, or actively trying to conceive should not use Mounjaro. The medicine is not licensed for under-18s. Certain conditions, including a history of medullary thyroid carcinoma or pancreatitis, require prescriber discussion before treatment could be considered.

Step 3, Knowing the side-effect profile before you start

The most common side effects are gastrointestinal: nausea, diarrhoea, constipation, indigestion, and sometimes vomiting. These tend to be most noticeable in the first days after starting or after a dose increase, and they often settle within a week or two. The NHS tirzepatide medicines page lists these clearly and is worth bookmarking for reference.

There are rarer but more serious effects to know about. In January 2026, the MHRA issued a Drug Safety Update highlighting acute pancreatitis as an infrequent but potentially serious risk: if you develop severe stomach pain that spreads to your back, with or without vomiting, seek urgent medical attention rather than waiting for a routine call. Allergic reactions, gallbladder problems, and injection-site reactions are also documented. For a detailed look at one particular reported symptom, the Mounjaro and hoarse voice page addresses a question our prescribers hear regularly.

Mounjaro holds Black Triangle (▼) status, meaning the MHRA actively collects post-market data. Patients and carers can report suspected side effects at yellowcard.mhra.gov.uk, doing so contributes to the national safety picture for everyone using the medicine.

Step 4, Accessing Mounjaro safely in the UK

Mounjaro is a prescription-only medicine. The legal route is assessment by a qualified prescriber who can confirm suitability, issue a prescription, and arrange supply through a pharmacy registered with the GPhC. Sellers offering these medicines without a clinical assessment, or at prices far below the market rate, are a red flag: the MHRA has raided illicit manufacturing sites producing counterfeit tirzepatide pens, and fake pens have caused serious harm. Any online pharmacy you use should be verifiable on the GPhC pharmacy register.

The current UK cost picture for private Mounjaro is explained on our Eli Lilly price increase page, including the context of the September 2025 list-price change. For a full picture of what the mounjaro programme looks like (from the first pen through to dose titration) the Mounjaro treatment page covers the whole journey, including guidance on starting out on Mounjaro 2 and information on what to expect when you move up to Mounjaro 5.

If you are ready to find out whether you are clinically suitable, the next step is a conversation with a prescriber. Speak to our prescribers through a free consultation: a GPhC-registered Independent Prescriber reviews your answers the same day, not software.